Could a prostate cancer drug help women with Alzheimer's? new trial investigates
NCT ID NCT03649724
First seen Jun 18, 2026 · Last updated Jun 18, 2026
Summary
This study tests whether leuprolide, a hormone-blocking drug, can slow memory and thinking decline in postmenopausal women with mild Alzheimer's or mild cognitive impairment. Participants also take a standard Alzheimer's medication (donepezil). The trial involves 180 women across three sites and lasts 48 weeks, measuring changes in cognition, daily function, and brain biomarkers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Miami Miller School of Medicine
Boca Raton, Florida, 33433, United States
-
University of Wisconsin - Madison
Madison, Wisconsin, 53792, United States
-
Weill Medical College of Cornell University
New York, New York, 10021, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.